Tomaras Stylianos, Feist Eugen
Helios Fachklinik für Rheumatologie Vogelsang-Gommern, Sophie-von-Boetticher-Str. 1, 39245, Vogelsang-Gommern, Deutschland.
Inn Med (Heidelb). 2023 Feb;64(2):152-163. doi: 10.1007/s00108-023-01470-9. Epub 2023 Jan 27.
Extensive research work in the field of inflammatory myopathies over the past years has given us new insights into the classification and treatment of myositis. The myositis drug pipeline has never been stronger, although it is too early to know which products will eventually reach the market. Furthermore, in our review we try to summarize the latest German guidelines and recommendations on myositis that were recently published in June 2022. After reading this article, you should be able to describe practical considerations regarding the diagnosis, classification, and management of inflammatory myopathies. Additionally, you will be able to recognize myositis subgroups with a poor prognosis.
过去几年，在炎性肌病领域开展的大量研究工作让我们对肌炎的分类和治疗有了新的认识。尽管目前尚无法确定哪些产品最终能够上市，但治疗肌炎的药物研发进程从未如此强劲。此外，在我们的综述中，我们试图总结2022年6月最近发布的关于肌炎的最新德国指南和建议。阅读本文后，您应该能够描述炎性肌病诊断、分类和管理方面的实际考量因素。此外，您将能够识别预后不良的肌炎亚组。
